CLDX Celldex Therapeutics

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "” page of the "" section of the . A replay will be available for 90 days following the event.

About Celldex

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
09/09/2025

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Con...

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "” page of the "" section of the . A replay will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver life-changing therapies. We...

9h / 39m 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinop...

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today ...

August 19, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Second Quarter 2025 Financial Results and Provides Cor...

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of barzolvolimab in EoE and CIndU and Phase 1 study of CDX-622 in healthy volunteers in 2H 2025 HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Data Demonstrating Profound Long Term Improvement in ...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spont...

June 14, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phas...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new dat...

June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch